Search results for "CASS"

showing 10 items of 433 documents

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of ob…

2015

The ABCB1 gene encodes for P-glycoprotein (P-gp), an efflux pump for a variety of xenobiotics. The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes of standard chemotherapy (cytarabine plus anthracyclines) remains controversial. A systematic search was made of studies evaluating the association between ABCB1 polymorphisms 1236C>T, 2677G>T/A and 3435C>T and effectiveness variables. We found seven cohort studies (1241 patients) showing a significantly higher overall survival (OS) among carriers of the variant allele of 1236C>T at year 4 (odds ratio (OR): 1.47, 95% confidence interval (CI): 1.07-2.01), 2677G>T/A at years 4-5 (OR: 1.37, 95% CI: 1.01-1.86) and 3435C>T at year…

AdultMaleOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BAdolescentSubgroup analysisCohort StudiesYoung AdultInternal medicineGeneticsmedicineHumansAnthracyclinesChildAgedAged 80 and overPharmacologyGeneticsPolymorphism Geneticbusiness.industryStandard treatmentCytarabineInfantMyeloid leukemiaOdds ratioMiddle AgedConfidence intervalLeukemia Myeloid AcuteObservational Studies as TopicTreatment OutcomeChild PreschoolMeta-analysisCytarabineMolecular MedicineFemalebusinessmedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outco…

2005

AbstractPurpose: Human leukocyte antigen (HLA) class I antigen defects, which are frequently present in head and neck squamous cell carcinoma (HNSCC) cells may provide the tumor with an escape mechanism from immune surveillance. Scanty information is available about mechanisms underlying HLA class I antigen defects in both lesions and cell lines from HNSCC. In this study, we investigate the role of antigen processing machinery (APM) component abnormalities in the generation of deficient HLA class I surface expression of HNSCC cells.Experimental Design: Using immunohistochemistry, Western blot, and RT-PCR analyses we correlated the expression of the IFN-γ inducible proteasome subunits and of…

AdultMaleProteasome Endopeptidase ComplexCancer ResearchPathologymedicine.medical_specialtyBlotting WesternDown-RegulationHuman leukocyte antigenBiologyCell LineInterferon-gammaATP Binding Cassette Transporter Subfamily B Member 3HLA AntigensMultienzyme ComplexesCell Line TumorTumor Cells Culturedotorhinolaryngologic diseasesmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 2AgedReverse Transcriptase Polymerase Chain ReactionAntigen processingHistocompatibility Antigens Class ICancerMiddle Agedmedicine.diseaseImmunohistochemistrySurvival AnalysisHead and neck squamous-cell carcinomaGene Expression Regulation NeoplasticCysteine Endopeptidasesstomatognathic diseasesOncologyHead and Neck NeoplasmsCarcinoma Squamous Cellbiology.proteinImmunohistochemistryTAP2ATP-Binding Cassette TransportersFemaleTAP1Clinical Cancer Research
researchProduct

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

2011

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 …

AdultMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentDNA Mutational AnalysisPopulationSingle-nucleotide polymorphismLiver transplantationBiologyKidneyPolymorphism Single NucleotideGastroenterologyBiomarkers PharmacologicalTacrolimusWhite PeopleGene FrequencyInternal medicineGeneticsmedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1educationAllele frequencyAllelesKidney transplantationAgededucation.field_of_studyKidney metabolismGeneral MedicineMiddle Agedmedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationTransplantationsurgical procedures operativeItalyLiverImmunologySettore BIO/14 - FarmacologiaPharmacogenetics CYP3A5 ABCB1 TacrolimusTransplant patientsFemaleImmunosuppressive AgentsPolymorphism Restriction Fragment LengthInternational Journal of Molecular Medicine
researchProduct

Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders

2004

Mutations in ABCA1 have been shown to be the cause of Tangier disease (TD) and some forms of familial hypoalphalipoproteinemia (HA), two genetic disorders characterized by low plasma HDL levels. Here we report six subjects with low HDL, carrying seven ABCA1 mutations, six of which are previously unreported. Two mutations (R557X and H160FsX173) were predicted to generate short truncated proteins; two mutations (E284K and Y482C) were located in the first extracellular loop and two (R1901S and Q2196H) in the C-terminal cytoplasmic domain of ABCA1. Two subjects found to be compound heterozygotes for ABCA1 mutations did not have overt clinical manifestations of TD. Three subjects, all with prema…

AdultMalemedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BAdolescentPremature coronary artery diseaseTangier diseaseCoronary DiseaseBiologyGene mutationmedicine.disease_causeCompound heterozygosityTangier diseaseInternal medicineGenotypeABCA1 genemedicineHumansChildHypoalphalipoproteinemiaSelection BiasAgedApolipoproteins BGeneticsMutationFamilial defective Apo B (FDB)Apolipoprotein A-ICholesterol HDLnutritional and metabolic diseasesMiddle Agedmedicine.diseaseLipoprotein lipaseTangier disease; Familial HDL deficiency; ABCA1 gene; Familial defective Apo B (FDB); Lipoprotein lipase; Premature coronary artery diseaseEndocrinologyChild PreschoolMutationbiology.proteinlipids (amino acids peptides and proteins)Allelic heterogeneityATP-Binding Cassette TransportersFemaleCardiology and Cardiovascular MedicineFamilial HDL deficiencyATP Binding Cassette Transporter 1
researchProduct

Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: results from the population-based Hortega stu…

2009

The aim of the study was to determine the influence of twenty single nucleotide polymorphisms (SNPs) of the ABCA1, ABCG1, ABCG5 and ABCG8 genes on the plasmatic concentrations of total cholesterol (TC), HDL and LDL cholesterol (HDLc, LDLc) in the postprandial state with a representative Spanish Caucasian population (1473 individuals, 50.0% women, ages ranging 21-85 years). In men, subjects with the AA genotype of the ABCA1 rs2230806 (R219K) polymorphism were associated with increased plasma LDLc levels, while the ABCA1 haplotype, which included the rs2230806 A allele, was associated with higher TC and LDLc plasma concentrations. In women, significant relationships were found between rs18935…

AdultMalemedicine.medical_specialtyLipoproteinsBlood lipidsSingle-nucleotide polymorphismHyperlipidemiasBiologyPolymorphism Single Nucleotidechemistry.chemical_compoundHigh-density lipoproteinPolymorphism (computer science)Internal medicineGenotypemedicineHumansATP Binding Cassette Transporter Subfamily G Member 5AllelesATP Binding Cassette Transporter Subfamily G Member 1AgedGeneticsAged 80 and overCholesterolHaplotypeATP Binding Cassette Transporter Subfamily G Member 8Cholesterol HDLMiddle AgedAtherosclerosisPostprandial PeriodPostprandialEndocrinologyCholesterolchemistryHaplotypesSpainlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersFemaleCardiology and Cardiovascular MedicineATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer

2020

Importance Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored. Objective To identify genetic variants associated with pCIA. Design, Setting, and Participants In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Termi…

AdultOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BBiopsyBreast NeoplasmsGenome-wide association studyDocetaxelDermatologyPolymorphism Single Nucleotide030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBreast cancerRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGenetic Predisposition to DiseasePromoter Regions GeneticAdverse effectRetrospective StudiesDose-Response Relationship Drugbusiness.industryAge FactorsCase-control studyAlopeciaCommon Terminology Criteria for Adverse EventsRetrospective cohort studyOdds ratioMiddle Agedmedicine.diseaseEnhancer Elements GeneticDocetaxelCase-Control Studies030220 oncology & carcinogenesisFemalebusinessHair FollicleFollow-Up StudiesGenome-Wide Association Studymedicine.drugJAMA Dermatology
researchProduct

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.

2015

Lung transplant patients present important variability in immunosuppressant blood concentrations during the first months after transplantation. Pharmacogenetics could explain part of this interindividual variability. We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients). The genotype was correlated to the trough blood drug concentrations corrected for dose and body weight (C0/Dc). The ABCB1 variant in rs1045642 was associated with significantly hig…

Adultmedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatment<i>P</i>-glycoproteinSingle-nucleotide polymorphismPharmacologyP-glycoproteinGastroenterologyPolymorphism Single NucleotideCatalysisMycophenolic acidTacrolimusArticlelcsh:ChemistryInorganic ChemistryInternal medicineBlood drugmedicinelung transplantationLung transplantationCytochrome P-450 CYP3AHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopybiologyOrganic ChemistryGeneral MedicineMiddle AgedMycophenolic AcidTacrolimusMultidrug Resistance-Associated Protein 2Computer Science ApplicationsTransplantationlcsh:Biology (General)lcsh:QD1-999Pharmacogeneticsbiology.proteinMultidrug Resistance-Associated ProteinsSLCO1B1PharmacogeneticsImmunosuppressive Agentsmedicine.drugInternational journal of molecular sciences
researchProduct

LXR antagonists induce ABCD2 expression

2014

X-linked adrenoleukodystrophy (X-ALD) is a rare neurodegenerative disorder characterized by the accumulation of very-long-chain fatty acids resulting from a beta-oxidation defect. Oxidative stress and inflammation are also key components of the pathogenesis. X-ALD is caused by mutations in the ABCDI gene, which encodes for a peroxisomal half ABC transporter predicted to participate in the entry of VLCFA-CoA into the peroxisome, the unique site of their beta-oxidation. Two homologous peroxisomal ABC transporters, ABCD2 and ABCD3 have been proven to compensate for ABCD1 deficiency when overexpressed. Pharmacological induction of these target genes could therefore represent an alternative ther…

Agonistx-ald;very-long-chain fatty acid;lxr;hydroxycholesterol;abcd2medicine.medical_specialtymedicine.drug_classx-aldEndogenyContext (language use)ATP-binding cassette transporterBiologyATP Binding Cassette Transporter Subfamily DInternal medicinemedicineHumanslxr[ SDV.BDD ] Life Sciences [q-bio]/Development BiologyhydroxycholesterolLiver X receptorAdrenoleukodystrophyMolecular Biology[SDV.BDD]Life Sciences [q-bio]/Development BiologyLiver X ReceptorsFatty AcidsBiologie du développementNeurosciencesCell BiologyHep G2 CellsPeroxisomemedicine.diseaseOrphan Nuclear ReceptorsDevelopment BiologyHydroxycholesterolsvery-long-chain fatty acidOxidative StressEndocrinologyGene Expression RegulationCell cultureabcd2Neurons and Cognition[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cancer researchlipids (amino acids peptides and proteins)AdrenoleukodystrophyATP-Binding Cassette Transporters[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
researchProduct

TAP off - tumors on

1997

Abstract The molecular characterization of T-cell-defined tumor-associated antigens has provided targets for cell-mediated immunotherapy for malignant diseases. The success of this strategy is negatively influenced by structural and functional abnormalities of major histocompatibility complex (MHC) class I molecules, which provide tumor cells with resistance to T-cell-mediated immune recognition. This article reviews the physiology of the MHC class I processing machinery and describes the deficiencies of this pathway in malignant cells.

Antigen processingImmunologyAntigen presentationCD1Human leukocyte antigenBiologyMHC restrictionMajor histocompatibility complexMajor Histocompatibility ComplexAntigenATP Binding Cassette Transporter Subfamily B Member 3NeoplasmsMHC class IImmunologyTumor Cells Culturedbiology.proteinHumansATP-Binding Cassette TransportersATP Binding Cassette Transporter Subfamily B Member 2Immunology Today
researchProduct